Rhumbline Advisers Buys 8,780 Shares of Intra-Cellular Therapies Inc (ITCI)
Rhumbline Advisers raised its stake in shares of Intra-Cellular Therapies Inc (NASDAQ:ITCI) by 20.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 51,596 shares of the biopharmaceutical company’s stock after buying an additional 8,780 shares during the quarter. Rhumbline Advisers owned about 0.09% of Intra-Cellular Therapies worth $912,000 at the end of the most recent quarter.
A number of other large investors also recently made changes to their positions in ITCI. Atlantic Trust Group LLC purchased a new position in Intra-Cellular Therapies during the first quarter valued at $215,000. MetLife Investment Advisors LLC increased its holdings in shares of Intra-Cellular Therapies by 15.4% in the 1st quarter. MetLife Investment Advisors LLC now owns 19,606 shares of the biopharmaceutical company’s stock worth $413,000 after purchasing an additional 2,613 shares in the last quarter. ETF Managers Group LLC bought a new stake in shares of Intra-Cellular Therapies in the 1st quarter worth $460,000. Fox Run Management L.L.C. bought a new stake in shares of Intra-Cellular Therapies in the 2nd quarter worth $533,000. Finally, Wells Fargo & Company MN increased its holdings in shares of Intra-Cellular Therapies by 13.8% in the 1st quarter. Wells Fargo & Company MN now owns 25,352 shares of the biopharmaceutical company’s stock worth $534,000 after purchasing an additional 3,065 shares in the last quarter. Institutional investors and hedge funds own 71.53% of the company’s stock.
Intra-Cellular Therapies stock opened at $20.50 on Tuesday. Intra-Cellular Therapies Inc has a 12 month low of $13.93 and a 12 month high of $25.82.
A number of research firms have commented on ITCI. Cantor Fitzgerald began coverage on Intra-Cellular Therapies in a report on Thursday, August 23rd. They issued an “overweight” rating and a $32.00 target price for the company. Royal Bank of Canada reissued a “buy” rating and issued a $35.00 target price on shares of Intra-Cellular Therapies in a report on Friday, August 3rd. ValuEngine raised Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a report on Friday, August 3rd. Canaccord Genuity set a $31.00 target price on Intra-Cellular Therapies and gave the stock a “buy” rating in a report on Thursday, August 2nd. Finally, BidaskClub raised Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a report on Friday, July 6th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $28.00.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders.
Featured Article: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps
Want to see what other hedge funds are holding ITCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intra-Cellular Therapies Inc (NASDAQ:ITCI).
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.